FrancophonIA/ELRC3.0 huggingface dataset:
English: General disorders pyrexia, asthenia, fatigue face oedema, oedema e, chills, body temperature increased, gait abnormal, thirst, chest pain, chest discomfort, malaise hypothermia c, body temperature decreased c, drug withdrawal syndrome induration
Swedish: Allmänna symtom och/eller symtom vid administrering sstället pyrexi, asteni, utmattning ansiktsödem, ödem e, frossa, ökad kroppstemperatur, onormal gång, ökad törst, bröstkorgssmärta, obehag i bröstkorgen, sjukdomskänsla hypotermi c,
English: • abdominal pain, abdominal discomfort, vomiting, nausea, constipation, diarrhoea, indigestion,
Swedish: • obehag eller smärta från buken, kräkningar, illamående, förstoppning, diarré, magbesvär, torr mun, tandvärk
English: Each prolonged-release tablet contains 9 mg of paliperidone.
Swedish: Varje depottablett innehåller 9 mg paliperidon.
English: Hypromellose Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (red) (E172) Carnauba wax
Swedish: Hypromellos Titandioxid (E171) Polyetylenglykol 400 Järnoxid (röd) (E172) Karnaubavax
English: Titanium dioxide (E171) Polyethylene glycol 400 Ferric oxide (yellow) (E172) Carnauba wax
Swedish: Hypromellos Titandioxid (E171) Polyetylenglykol 400 Järnoxid (gul) (E172) Karnaubavax
English: Each INVEGA 9 mg prolonged-release tablet contains 9 mg of paliperidone.
Swedish: Varje INVEGA 9 mg depottablett innehåller 9 mg paliperidon.
English: • lung congestion
Swedish: • näsblödningar
English: Each prolonged-release tablet contains 3 mg of paliperidone.
Swedish: Varje depottablett innehåller 3 mg paliperidon.
English: Cardiac disorders atrioventricular block, conduction disorder, electrocardiogra m QT prolonged, bradycardia,
Swedish: Hjärtat atrioventrikulärt block, retledningsstörningar, QTförlängning på EKG, bradykardi, takykardi sinusarytmi, onormalt EKG, palpitationer förmaksflimmer, posturalt ortostatiskt takykardisyndrom
English: Each prolonged-release tablet contains 12 mg of paliperidone.
Swedish: Varje depottablett innehåller 12 mg paliperidon.
English: hypersensitivity
Swedish: Fuktkänsligt
English: 30 prolonged-release tablets - EU/1/07/395/057 350 prolonged-release tablets - EU/1/07/395/058
Swedish: 30 depottabletter - EU/1/07/395/057 350 depottabletter - EU/1/07/395/058
English: headache dystonia b, dizziness, dyskinesia b,
Swedish: Centrala och perifera nervsystemet parkinsonism b, akatisi b, sedation/ somnolens, huvudvärk dystoni b, yrsel, dyskinesi b,
English: 30 prolonged-release tablets - EU/1/07/395/063 350 prolonged-release tablets - EU/1/07/395/064
Swedish: 30 depottabletter - EU/1/07/395/063 350 depottabletter - EU/1/07/395/064
English: Each INVEGA 12 mg prolonged-release tablet contains 12 mg of paliperidone.
Swedish: Varje INVEGA 12 mg depottablett innehåller 12 mg paliperidon.
English: Each INVEGA 6 mg prolonged-release tablet contains 6 mg of paliperidone.
Swedish: Varje INVEGA 6 mg depottablett innehåller 6 mg paliperidon.
English: 30 prolonged-release tablets - EU/1/07/395/061 350 prolonged-release tablets - EU/1/07/395/062
Swedish: 30 depottabletter - EU/1/07/395/061 350 depottabletter - EU/1/07/395/062
English: Each prolonged-release tablet contains 6 mg of paliperidone.
Swedish: Varje depottablett innehåller 6 mg paliperidon.
English: Hepatic impairment
Swedish: influensaliknande känsla
English: 30 prolonged-release tablets - EU/1/07/395/059 350 prolonged-release tablets - EU/1/07/395/060
Swedish: 30 depottabletter - EU/1/07/395/059 350 depottabletter - EU/1/07/395/060
English: • missed menstrual periods or other problems with your cycle (females), leakage of milk from the breasts, sexual dysfunction, breast pain, breast discomfort
Swedish: • uteblivna menstruationsperioder eller andra problem med menstruationscykeln (kvinnor),
English: Overcoat
Swedish: Kramper
English: 14 prolonged-release tablets - EU/1/07/395/074 - CLEAR 28 prolonged-release tablets - EU/1/07/395/016 - CLEAR 30 prolonged-release tablets - EU/1/07/395/017 - CLEAR 49 prolonged-release tablets - EU/1/07/395/018 - CLEAR 56 prolonged-release tablets - EU/1/07/395/019 - CLEAR 98 prolonged-release tablets - EU/1/07/395/020 - CLEAR
Swedish: 14 depottabletter - EU/1/07/395/074 - GENOMSKINLIG 28 depottabletter - EU/1/07/395/016 - GENOMSKINLIG 30 depottabletter - EU/1/07/395/017 - GENOMSKINLIG 49 depottabletter - EU/1/07/395/018 - GENOMSKINLIG 56 depottabletter - EU/1/07/395/019 - GENOMSKINLIG 98 depottabletter - EU/1/07/395/020 - GENOMSKINLIG
English: 14 prolonged-release tablets - EU/1/07/395/070 28 prolonged-release tablets - EU/1/07/395/045 49 prolonged-release tablets - EU/1/07/395/046 56 prolonged-release tablets - EU/1/07/395/047 98 prolonged-release tablets - EU/1/07/395/048
Swedish: 14 depottabletter - EU/1/07/395/070 28 depottabletter - EU/1/07/395/045 49 depottabletter - EU/1/07/395/046 56 depottabletter - EU/1/07/395/047 98 depottabletter - EU/1/07/395/048
English: 14 prolonged-release tablets - EU/1/07/395/071 - CLEAR 28 prolonged-release tablets - EU/1/07/395/011 - CLEAR 30 prolonged-release tablets - EU/1/07/395/012 - CLEAR 49 prolonged-release tablets - EU/1/07/395/013 - CLEAR 56 prolonged-release tablets - EU/1/07/395/014 - CLEAR 98 prolonged-release tablets - EU/1/07/395/015 - CLEAR
Swedish: 14 depottabletter - EU/1/07/395/071 - GENOMSKINLIG 28 depottabletter - EU/1/07/395/011 - GENOMSKINLIG 30 depottabletter - EU/1/07/395/012 - GENOMSKINLIG 49 depottabletter - EU/1/07/395/013 - GENOMSKINLIG 56 depottabletter - EU/1/07/395/014 - GENOMSKINLIG 98 depottabletter - EU/1/07/395/015 - GENOMSKINLIG
English: EU/1/07/395/001 - 005 EU/1/07/395/021 - 025 EU/1/07/395/041 - 044 EU/1/07/395/057 - 058 EU/1/07/395/065 - 067
Swedish: EU/1/07/395/041 - 044 EU/1/07/395/057 - 058 EU/1/07/395/065 - 067
English: Each INVEGA 3 mg prolonged-release tablet contains 3 mg of paliperidone.
Swedish: Den aktiva substansen är paliperidon Varje INVEGA 3 mg depottablett innehåller 3 mg paliperidon.
English: 14 prolonged-release tablets - EU/1/07/395/076 28 prolonged-release tablets - EU/1/07/395/053 49 prolonged-release tablets - EU/1/07/395/054 56 prolonged-release tablets - EU/1/07/395/055 98 prolonged-release tablets - EU/1/07/395/056
Swedish: 14 depottabletter - EU/1/07/395/076 28 depottabletter - EU/1/07/395/053 49 depottabletter - EU/1/07/395/054 56 depottabletter - EU/1/07/395/055 98 depottabletter - EU/1/07/395/056
English: 14 prolonged-release tablets - EU/1/07/395/067 28 prolonged-release tablets - EU/1/07/395/041 49 prolonged-release tablets - EU/1/07/395/042 56 prolonged-release tablets - EU/1/07/395/043 98 prolonged-release tablets - EU/1/07/395/044
Swedish: 14 depottabletter - EU/1/07/395/067 28 depottabletter - EU/1/07/395/041 49 depottabletter - EU/1/07/395/042 56 depottabletter - EU/1/07/395/043 98 depottabletter - EU/1/07/395/044
English: 14 prolonged-release tablets - EU/1/07/395/073 28 prolonged-release tablets - EU/1/07/395/049 49 prolonged-release tablets - EU/1/07/395/050 56 prolonged-release tablets - EU/1/07/395/051 98 prolonged-release tablets - EU/1/07/395/052
Swedish: 14 depottabletter - EU/1/07/395/073 28 depottabletter - EU/1/07/395/049 49 depottabletter - EU/1/07/395/050 56 depottabletter - EU/1/07/395/051 98 depottabletter - EU/1/07/395/052
English: 14 prolonged-release tablets - EU/1/07/395/065 - CLEAR 28 prolonged-release tablets - EU/1/07/395/001 - CLEAR 30 prolonged-release tablets - EU/1/07/395/002 - CLEAR 49 prolonged-release tablets - EU/1/07/395/003 - CLEAR 56 prolonged-release tablets - EU/1/07/395/004 - CLEAR 98 prolonged-release tablets - EU/1/07/395/005 - CLEAR
Swedish: 14 depottabletter - EU/1/07/395/065 - GENOMSKINLIG 28 depottabletter - EU/1/07/395/001 - GENOMSKINLIG 30 depottabletter - EU/1/07/395/002 - GENOMSKINLIG 49 depottabletter - EU/1/07/395/003 - GENOMSKINLIG 56 depottabletter - EU/1/07/395/004 - GENOMSKINLIG 98 depottabletter - EU/1/07/395/005 - GENOMSKINLIG
English: 14 prolonged-release tablets - EU/1/07/395/068 - CLEAR 28 prolonged-release tablets - EU/1/07/395/006 - CLEAR 30 prolonged-release tablets - EU/1/07/395/007 - CLEAR 49 prolonged-release tablets - EU/1/07/395/008 - CLEAR 56 prolonged-release tablets - EU/1/07/395/009 - CLEAR 98 prolonged-release tablets - EU/1/07/395/010 - CLEAR
Swedish: 14 depottabletter - EU/1/07/395/068 - GENOMSKINLIG 28 depottabletter - EU/1/07/395/006 - GENOMSKINLIG 30 depottabletter - EU/1/07/395/007 - GENOMSKINLIG 49 depottabletter - EU/1/07/395/008 - GENOMSKINLIG 56 depottabletter - EU/1/07/395/009 - GENOMSKINLIG 98 depottabletter - EU/1/07/395/010 - GENOMSKINLIG
English: 14 prolonged-release tablets - EU/1/07/395/075 - WHITE 28 prolonged-release tablets - EU/1/07/395/036 - WHITE 30 prolonged-release tablets - EU/1/07/395/037 - WHITE 49 prolonged-release tablets - EU/1/07/395/038 - WHITE 56 prolonged-release tablets - EU/1/07/395/039 - WHITE 98 prolonged-release tablets - EU/1/07/395/040 - WHITE
Swedish: 14 depottabletter - EU/1/07/395/075 - VIT 28 depottabletter - EU/1/07/395/036 - VIT 30 depottabletter - EU/1/07/395/037 - VIT 49 depottabletter - EU/1/07/395/038 - VIT 56 depottabletter - EU/1/07/395/039 - VIT 98 depottabletter - EU/1/07/395/040 - VIT
English: • stomach pain
Swedish: • dimsyn
English: 14 prolonged-release tablets - EU/1/07/395/066 - WHITE 28 prolonged-release tablets - EU/1/07/395/021 - WHITE 30 prolonged-release tablets - EU/1/07/395/022 - WHITE 49 prolonged-release tablets - EU/1/07/395/023 - WHITE 56 prolonged-release tablets - EU/1/07/395/024 - WHITE 98 prolonged-release tablets - EU/1/07/395/025 - WHITE
Swedish: 14 depottabletter - EU/1/07/395/066 - VIT 28 depottabletter - EU/1/07/395/021 - VIT 30 depottabletter - EU/1/07/395/022 - VIT 49 depottabletter - EU/1/07/395/023 - VIT 56 depottabletter - EU/1/07/395/024 - VIT 98 depottabletter - EU/1/07/395/025 - VIT
English: You should be aware that both of these conditions may be caused by this type of medicine.
Swedish: • om du någon gång har haft avvikande rörelser i tunga eller ansikte (tardiv dyskinesi).Du bör känna till att båda dessa tillstånd kan orsakas av denna typ av läkemedel.
English: Core
Swedish: Kön
English: Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Swedish: Butylhydroxitoluen (E321) Polyetylenoxid 7000K Järnoxid (röd) (E172) Hydroxietylcellulosa Polyetylenglykol 3350 Cellulosaacetat
English: 14 prolonged-release tablets - EU/1/07/395/072 - WHITE 28 prolonged-release tablets - EU/1/07/395/031 - WHITE 30 prolonged-release tablets - EU/1/07/395/032 - WHITE 49 prolonged-release tablets - EU/1/07/395/033 - WHITE 56 prolonged-release tablets - EU/1/07/395/034 - WHITE 98 prolonged-release tablets - EU/1/07/395/035 - WHITE
Swedish: 14 depottabletter - EU/1/07/395/072 - VIT 28 depottabletter - EU/1/07/395/031 - VIT 30 depottabletter - EU/1/07/395/032 - VIT 49 depottabletter - EU/1/07/395/033 - VIT 56 depottabletter - EU/1/07/395/034 - VIT 98 depottabletter - EU/1/07/395/035 - VIT
English: Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Ferric oxide (yellow) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Swedish: Butylhydroxitoluen (E321) Polyetylenoxid 7000K Järnoxid (röd) (E172) Järnoxid (gul) (E172) Hydroxietylcellulosa Polyetylenglykol 3350 Cellulosaacetat
English: Butyl hydroxytoluene (E321) Polyethylene oxide 7000K Ferric oxide (red) (E172) Iron oxide (black) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Swedish: Butylhydroxitoluen (E321) Polyetylenoxid 7000K Järnoxid (röd) (E172) Järnoxid (svart) (E172) Hydroxietylcellulosa Polyetylenglykol 3350 Cellulosaacetat
English: Butyl hydroxytoluene (E321) Ferric oxide (yellow) (E172) Polyethylene oxide 7000K Ferric oxide (red) (E172) Hydroxyethyl cellulose Polyethylene glycol 3350 Cellulose acetate
Swedish: Butylhydroxitoluen (E321) Järnoxid (gul) (E172) Polyetylenoxid 7000K Järnoxid (röd) (E172) Hydroxietylcellulosa Polyetylenglykol 3350 Cellulosaacetat
English: LOCF endpoint change from baseline
Swedish: Förändring från baslinjevärde till effektmått-LOCF.
English: Placebo) Diff. of LS Means (SE)
Swedish: P-värde (vs placebo)
English: Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, Marketing Authorisation Holders in the Member States
Swedish: Bilaga I Förteckning över läkemedlets namn, läkemedelsform, styrka, administreringssätt av läkemedlet samt innehavare av godkännande för försäljning i medlemsstaterna
English: Heinzelova 62a 10 000 Zagreb Croatia
Swedish: Heinzelova 62a 10 000 Zagreb Kroatien
English: Bucureşti-Ploieşti Nr. 1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti Romania
Swedish: Bucureşti-Ploieşti Nr. 1A, Clădirea C1, Etaj 3, Sector 1, Bucureşti Rumänien
English: 174 56 Alimos Greece
Swedish: 174 56 Alimos Grekland
English: Via Vitorchiano 151 00189 Roma Italy
Swedish: Via Vitorchiano 151 00189 Roma Italien
English: 34 avenue Léonard de Vinci 92400 Courbevoie France
Swedish: 34 avenue Léonard de Vinci 92400 Courbevoie Frankrike
English: Red Oak North South County Business Park Leopardstown
Swedish: South County Business Park Leopardstown
English: 0.05% w/w Mometasone furoate (monohydrate) calculated on the anhydrous basis
Swedish: Nasal användning 0,05% w/w mometasonfuroat (monohydrat) beräknat på vattenfri substans
English: Merck Sharp and Dohme Bulgaria EOOD 55, Nikola Vaptzarov blvd. EXPO 2000, East Wing, Sectors B1 & B2
Swedish: 55, Nikola Vaptzarov blvd. EXPO 2000, East Wing, Sectors B1 & B2
English: Belgium MSD Belgium BVBA/SPRL Clos du Lynx 5
Swedish: MSD Belgium BVBA/SPRL Clos du Lynx 5
English: Luxembourg MSD Belgium BVBA/SPRL Clos du Lynx 5
Swedish: Luxemburg MSD Belgium BVBA/SPRL Clos du Lynx 5
English: Merck Sharp & Dohme Ireland (Human Health) Limited
Swedish: Merck Sharp & Dohme Ireland (Human Health) Limited Red Oak North
English: 2031 BN Haarlem P.O.
Swedish: 2031 BN Haarlem P.O. Box 581
English: Šmartinska cesta 140 1000 Ljubljana Slovenia
Swedish: Šmartinska cesta 140
English: Malesci Istituto Farmacobiologico S.p.A Via Lungo l'Ema 7 Bagno a Ripoli (FI) Italy
Swedish: Malesci Istituto Farmacobiologico S.p.A
English: Denmark Merck Sharp & Dohme BV Waarderweg 39
Swedish: Merck Sharp & Dohme BV Waarderweg 39
English: Merck Sharp & Dohme Ltd Hertford Road Hoddesdon
Swedish: Storbritannien Merck Sharp & Dohme Ltd Hertford Road
English: Sweden Merck Sharp & Dohme B.V.
Swedish: Nederländerna Merck Sharp & Dohme B.V.
English: Germany MSD SHARP & DOHME GMBH
Swedish: MSD SHARP & DOHME GMBH Lindenplatz 1
English: 1 year
Swedish: 1 år.
English: Plasma protein binding is 91%.
Swedish: Plasmaproteinbindningen är 91%.
English: In the MRP the United Kingdom is the Reference Member State and Austria, Belgium, Denmark, Finland, France, Greece, Germany, Italy, Ireland, Iceland, Luxembourg, The Netherlands, Portugal, Spain and Sweden are Concerned Member States.
Swedish: I förfarandet för ömsesidigt erkännande är Storbritannien referensmedlemsstat, medan Österrike, Belgien, Danmark, Finland, Frankrike, Grekland, Tyskland, Italien, Irland, Island, Luxemburg, Nederländerna, Portugal, Spanien och Sverige är de berörda medlemsstaterna.
English: Continue holding your breath for a few seconds, or as long as is comfortable.
Swedish: Fortsätt att hålla andan i några sekunder eller så länge som det känns bekvämt.
English: Patients should not rush stages 4, 5 and 6.
Swedish: Att inte skynda igenom punkterna 4, 5 och 6.
English: Treatment with Seretide should not be stopped abruptly.
Swedish: Behandling med Seretide skall inte avbrytas abrupt.
English: Less than 5% of the dose is excreted in urine, mainly as metabolites.
Swedish: Mindre än 5% av dosen utsöndras i urinen huvudsakligen som metaboliter.
English: 15232 Halandri, Athens Greece
Swedish: 15232 Halandri, Athens, Grekland
English: Do not stop taking Seretide suddenly as this could make your asthma worse and could cause problems with the body's hormones.
Swedish: Sluta inte plötsligt att ta Seretide då detta kan förvärra dina symtom och orsaka problem med kroppens hormoner.
English: Important, do not rush steps 4 to 7: 4.
Swedish: Det är viktigt att inte skynda genom punkterna 4-7
English: OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF SERETIDE EVOHALER AND ASSOCIATED NAMES (SEE ANNEX I)
Swedish: ÖVERGRIPANDE SAMMANFATTNING AV DEN VETENSKAPLIGA UTVÄRDERINGEN AV SERETIDE EVOHALER (MED SYNONYMER (SE BILAGA I)
English: It is very important to follow your doctor's instructions as to how many puffs to inhale and how often to take your medicine.
Swedish: Det är viktigt att följa läkarens ordination hur många inhalationer som du ska ta och hur ofta.
English: If you have diabetes, more frequent blood sugar monitoring and possibly adjustment of your usual diabetic treatment may be required.
Swedish: Om du har diabetes, kan du behöva göra tätare blodsockerkontroller och eventuellt ändra din vanliga diabetesbehandling
English: Concomitant use of other beta-adrenergic containing drugs can have a potentially additive effect.
Swedish: Samtidig användning av andra beta-adrenerga medel kan ha en potentiell additiv effekt.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 120 puffs
Swedish: MÄNGD UTTRYCKT I VIKT, VOLYM ELLER PER ENHET 120 doser
English: Percentage of Patients Attaining *Well Controlled (WC) and **Totally Controlled (TC) Asthma over 12 months
Swedish: Antal patienter (i procent) som uppnådde *Väl-kontrollerad (WC) och **Totalkontrollerad (TC) astma under 12 månader Salmeterol/FP
English: Both non-selective and selective beta-blockers should be avoided in patients with asthma, unless there are compelling reasons for their use.
Swedish: Både selektiva och icke-selektiva beta-blockerare skall undvikas till patienter med astma såvida ej tvingande skäl föreligger.
English: You should be standing or sitting whilst using the inhaler.
Swedish: Du bör sitta eller stå när du inhalerar.
English: The main part of the dose is excreted as faeces as metabolites and unchanged drug.
Swedish: Större delen av dosen utsöndras i feces som metaboliter och oförändrat läkemedel.
English: 3 X 120 puffs
Swedish: 3 x 120 doser
English: It should be noted that this could potentially lead to an increase in the risk of systemic adverse effects.
Swedish: Detta kan möjligen leda till ökad risk för systemeffekter.
English: In several EU Member States Seretide Evohaler and associated names (see Annex I) are approved through the Mutual Recognition Procedure (MRP).
Swedish: Seretide Evohaler med synonymer har godkänts i flera av EU:s medlemsstater genom förfarandet för ömsesidigt erkännande (se bilaga I).
English: Note: This Annex III (Summary of Product Characteristics, Labelling and Package Leaflet) is the one that was Annexed to the Commission Decision on this Article 6(13) referral for Seretide Evohaler and associated names.
Swedish: Denna bilaga III (produktresume, märking och bipacksedel) var bilagd till kommissionens beslut för detta hänskjutande enligt artikel 6(13) för Seretide Evohaler med synonymer.
English: Stop using the inhaler when the counter reads 000.
Swedish: Sluta använda inhalatorn när dosräknaren visar 000.
English: SPECIAL STORAGE CONDITIONS Do not store above 25°C
Swedish: SÄRSKILDA FÖRVARINGSANVISNINGAR Förvaras vid högst 25oC
English: The time on treatment for 50% of subjects to achieve a first individual Well-Controlled week was 16 days for Seretide compared to 37 days for the ICS group.
Swedish: Behandlingstiden för 50% av deltagarna att uppnå en första välkontrollerad vecka var 16 dagar för Seretide jämfört med 37 dagar för inhalerad kortikosteroid.
English: - Very fast heart rate (tachycardia).
Swedish: - Mycket snabb hjärtfrekvens (takykardi)
English: It is important that patients start to breathe in as slowly as possible just before operating their inhaler.
Swedish: Det är viktigt att att andas in så sakta som möjligt innan man använder inhalationssprayen.
English: Increasing use of short-acting bronchodilators to relieve asthma symptoms indicates deterioration of asthma control and patients should be reviewed by a physician.
Swedish: Ökad användning av kortverkande bronkdilaterare för att lindra astmasymtom tyder på försämrad astmakontroll, varför patienten bör undersökas av läkare.
English: The doctor will prescribe the lowest strength of Seretide Evohaler that will best control your symptoms.
Swedish: Din läkare kommer att ordinera den lägsta styrka av Seretide Evohaler som bäst håller dina besvär under kontroll.
English: Seretide contains salmeterol and fluticasone propionate which have differing modes of action.
Swedish: Seretide innehåller salmeterol och flutikasonpropionat som har olika verkningsmekanismer.
English: Potentially serious hypokalaemia may result from systemic beta-2-agonist therapy, but following inhalation at therapeutic doses plasma levels of salmeterol are very low.
Swedish: Potentiellt allvarlig hypokalemi kan uppkomma efter behandling med perorala beta-2-agonister men efter inhalation i terapeutiska doser är plasmanivåerna av salmeterol låga.
English: Children and adolescents <16years taking high doses of fluticasone (typically ≥ 1000mcg/day) may be at particular risk.
Swedish: Barn och ungdom under 16 år som får höga doser av flutikasonpropionat (vanligen > 1000 mikrogram per dag) är en speciell riskgrupp.
English: GOAL showed more patients treated with Seretide achieved asthma control than patients treated with ICS alone and this control was attained at a lower corticosteroid dose.
Swedish: GOAL visade att fler patienter som behandlades med Seretide uppnådde astmakontroll än patienter som behandlades enbart med inhalerad kortikosteroid och denna kontroll uppnåddes med en lägre kortikosteroiddos.
English: Adverse events which have been associated with salmeterol/fluticasone propionate are given below, listed by system organ class and frequency.
Swedish: Biverkningar som har relaterats till salmeterol/flutikasonpropionat anges nedan och är klassificerade efter organsystem och frekvens.
English: If Seretide therapy has to be withdrawn due to overdose of the beta agonist component of the drug, provision of appropriate replacement steroid therapy should be considered.
Swedish: Om behandling med Seretide måste avbrytas på grund av överdosering av beta-agonistkomponenten, bör ersättning med lämplig steroidterapi övervägas.
English: To prevent your inhaler blocking up, it is important to clean it at least once a week.
Swedish: För att förhindra att inhalatorn 'pluggar igen' är det viktigt att inhalatorn rengörs minst en gång i veckan:
English: Check inside and outside to make sure that the mouthpiece is clean and that there are no foreign objects.
Swedish: Kontrollera att munstycket är rent på in- och utsidan och att det inte finns några främmande föremål.
English: Seretide Evohaler is for inhalation use only.
Swedish: Seretide Evohaler är endast avsedd för inhalation.
English: United Kingdom Glaxo Wellcome UK Limited, Stockley Park West, Uxbridge Middlesex UB11 1BT
Swedish: Glaxo Wellcome UK Limited, trading as Allen & Hanburys Stockley Park West, Uxbridge, Middlesex UB11 1BT, Förenade kungariket
English: METHOD OF ADMINISTRATION Shake well before use Read the package leaflet before use
Swedish: ADMINISTRERINGSSÄTT Omskakas före användning Läs bipacksedeln före användning
English: The inhaler has been designed for use in a vertical position.
Swedish: Inhalationssprayen har utformats att användas i upprätt läge.
English: Do not put the metal container in water.
Swedish: Lägg inte metallbehållaren i vatten.
English: Take care not to drop the inhaler as this may cause the counter to count down.
Swedish: Var försiktig så att du inte tappar inhalationssprayen, eftersom det kan hända att dosräknaren aktiveras och räknar ner.
English: Do not remove the canister from the plastic casing.
Swedish: Tag inte bort metallbehållaren från plastinhalatorn.
English: Seretide Evohaler United Kingdom Seretide Evohaler
Swedish: Seretide Evohaler Storbritannien Seretide Evohaler
English: Well-Controlled asthma was achieved more rapidly with Seretide than with ICS alone.
Swedish: Välkontrollerad astma uppnåddes snabbare med Seretide än med enbart inhalerad kortikosteroid.
English: Patients should consider getting a replacement when the counter shows the number 020.
Swedish: Att patienten bör se till att ha en ny inhalationsspray till hands när dosräknaren visar 020.